NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis $2.77 -0.03 (-1.07%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Lantern Pharma Stock (NASDAQ:LTRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lantern Pharma alerts:Sign Up Key Stats Today's Range$2.71▼$2.9050-Day Range$2.51▼$4.1752-Week Range$1.11▼$5.28Volume14,711 shsAverage Volume342,482 shsMarket Capitalization$35.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lantern Pharma, Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment. The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies. Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.AI Generated. May Contain Errors. Read More Lantern Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreLTRN MarketRank™: Lantern Pharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 843rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLantern Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLantern Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Lantern Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantern Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.10% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 5.13.Change versus previous monthShort interest in Lantern Pharma has recently increased by 1.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentLantern Pharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lantern Pharma this week, compared to 2 articles on an average week. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Lantern Pharma in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $200,001.00 in company stock, which represents 0.5557% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,001.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders8.50% of the stock of Lantern Pharma is held by insiders.Percentage Held by Institutions28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTRN Stock News HeadlinesLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...August 4 at 8:45 AM | finance.yahoo.comLantern Pharma Spins Off Open-Medicine AI PlatformAugust 3 at 6:30 PM | tipranks.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 6 at 1:00 AM | Altimetry (Ad)Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of MedicineAugust 3 at 7:30 AM | businesswire.comLantern Pharma (NASDAQ:LTRN) Shares Down 3.5% - Here's WhyJuly 30, 2026 | americanbankingnews.comLantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder CancerJuly 28, 2026 | businesswire.comLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor CancersJuly 23, 2026 | businesswire.comLantern Pharma Launches ZetaOmics™ - an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every CancerJuly 8, 2026 | tmcnet.comSee More Headlines LTRN Stock Analysis - Frequently Asked Questions How have LTRN shares performed this year? Lantern Pharma's stock was trading at $3.03 at the beginning of the year. Since then, LTRN stock has decreased by 6.9% and is now trading at $2.8210. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $28 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,750,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO). Company Calendar Last Earnings5/15/2026Today8/06/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 LTRN's financial health is in the Green zone, according to TradeSmith. LTRN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LTRN CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees20Year Founded2013Profitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-198.34% Return on Assets-129.08% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book4.78Miscellaneous Outstanding Shares12,759,000Free Float11,674,000Market Cap$35.34 million OptionableOptionable Beta2.34 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LTRN) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredWhite House Insider: “President Trump is Getting Backstabbed!”A high-level White House insider and lifelong friend of the Trump family recently went on camera with a warnin...Paradigm Press | SponsoredThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
